Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lémann Index and Inflammatory Bowel Disease Disability Index.

Tytuł:: Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lémann Index and Inflammatory Bowel Disease Disability Index.
Autorzy:: Lauriot Dit Prevost C; Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France.
Azahaf M; Department of Digestive Diagnostic and Interventional Radiology, Claude Huriez Hospital, University of Lille, Lille, France.
Nachury M; Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France.
Branche J; Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France.
Gerard R; Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France.
Wils P; Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France.
Lambin T; Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France.
Desreumaux P; Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France.
Ernst O; Department of Digestive Diagnostic and Interventional Radiology, Claude Huriez Hospital, University of Lille, Lille, France.
Pariente B; Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France.
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 May; Vol. 51 (9), pp. 889-898. Date of Electronic Publication: 2020 Mar 27.
Typ publikacji:: Journal Article; Observational Study
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987-
MeSH Terms:: Health Status Indicators*
Crohn Disease/*diagnosis
Intestines/*pathology
Intestines/*physiopathology
Adolescent ; Adult ; Cohort Studies ; Crohn Disease/drug therapy ; Crohn Disease/pathology ; Crohn Disease/physiopathology ; Disability Evaluation ; Female ; France ; Humans ; Immunosuppressive Agents/therapeutic use ; Intestines/drug effects ; Male ; Middle Aged ; Prospective Studies ; Severity of Illness Index ; Surveys and Questionnaires ; Tertiary Care Centers ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/immunology ; Young Adult
References:: Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415-1422.
Peyrin-Biroulet L, Loftus EV, Colombel J-F, Sandborn WJ. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297.
Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29:397-404.
Panaccione R, Colombel J-F, Louis E, Peyrin-Biroulet L, Sandborn WJ. Evolving definitions of remission in Crohn’s disease. Inflamm Bowel Dis. 2013;19:1645-1653.
Colombel J-F, Mahadevan U. Inflammatory bowel disease 2017: innovations and changing paradigms. Gastroenterology. 2017;152:309-312.
Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61:241-247.
Gower-Rousseau C, Sarter H, Savoye G, et al. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2015. gutjnl-2015-310151.
Pariente B, Mary J-Y, Danese S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148:52-63.e3.
Fiorino G, Bonifacio C, Allocca M, et al. Bowel damage as assessed by the Lémann Index is Reversible on anti-TNF Therapy for Crohn’s Disease. J Crohns Colitis. 2015;9:633-639.
Bodini G, Giannini EG, De Maria C, Dulbecco P, Furnari M, Marabotto E, et al. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn’s disease. A study performed using the Lémann Index. Dig Liver Dis [Internet]. 2016. http://linkinghub.elsevier.com/retrieve/pii/S1590865816307800 (accessed January 22, 2017).
Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3-25.
Amitai MM, Zarchin M, Lahat A, et al. Structural bowel damage in quiescent Crohn’s disease. Dig Liver Dis [Internet], 2017. http://linkinghub.elsevier.com/retrieve/pii/S1590865817302013 (accessed April 8, 2017).
Fiorino G, Morin M, Bonovas S, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017;11:274-280.
Gilletta C, Lewin M, Bourrier A, et al. Changes in the Lémann Index values during the first years of Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1633-1640.e3.
Bhagya Rao B, Koutroubakis IE, Rivers CR, et al. Correlation of anemia status with worsening bowel damage as measured by Lémann Index in patients with Crohn’s disease. Dig Liver Dis. 2016;48:626-631.
Lunder AK, Jahnsen J, Bakstad LT, et al. Bowel damage in patients with long-term Crohn’s disease, assessed by magnetic resonance enterography and the Lémann Index. Clin Gastroenterol Hepatol. 2018;16:75-82.e5.
D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. The Lancet. 2008;371:660-667.
Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet Lond Engl. 2015;386:1825-1834.
Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis. 2013;7:213-221.
Oh EH, Oh K, Han M, et al. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn’s disease with poor prognostic factors. PLoS ONE. 2017;12:e0177479.
Yzet C. Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM. ECCO. 2019.
Soares JB, Pereira R, Costa JM, Arroja B, Gonçalves R. The Inflammatory Bowel Disease-Disability Index: validation of the Portuguese version according to the COSMIN checklist. Eur J Gastroenterol Hepatol. 2016;28:1151-1160.
Leong RWL, Huang T, Ko Y, et al. Prospective validation study of the International Classification of Functioning, Disability and Health score in Crohn’s disease and ulcerative colitis. J Crohns Colitis. 2014;8:1237-1245.
Lapidus A, Bernell O, Hellers G, Löfberg R. Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology. 1998;114:1151-1160.
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre J-P, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650-656.
Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical prognostic factors for disabling Crohn’s disease: a systematic review and meta-analysis. World J Gastroenterol. 2013;19:3866-3871.
Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45:933-940.
Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatol Oxf Engl. 2000;39:122-132.
van der Have M, Fidder HH, Leenders M, et al. Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis. 2015;21:369-377.
Lo B, Prosberg MV, Gluud LL, et al. Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. Aliment Pharmacol Ther. 2018;47:6-15.
Substance Nomenclature:: 0 (Immunosuppressive Agents)
0 (Tumor Necrosis Factor-alpha)
Entry Date(s):: Date Created: 20200330 Date Completed: 20201002 Latest Revision: 20201002
Update Code:: 20240105
DOI:: 10.1111/apt.15681
PMID:: 32221985
: Czasopismo naukowe

Pełny tekst

Background: The notion of Crohn's disease (CD) as a chronic, progressive and disabling condition has led to the development of new indexes: the Lémann Index measuring cumulative bowel damage and the Inflammatory Bowel Disease (IBD) Disability Index, assessing functional disability.
Aims: To measure the Lémann Index and the IBD Disability Index in a large prospective cohort of CD patients and to assess the correlation between these two indexes.
Methods: We performed a prospective study in a tertiary referral centre including all consecutive CD outpatients. We assessed the Lémann Index and the IBD Disability Index questionnaire in all patients.
Results: One hundred and thirty CD patients were consecutively included. The mean Lémann Index (±SD) was 11.9 ± 14.1 and ranged from 0 to 72.5 points. Factors associated with a high bowel damage score were: disease duration, anal location, previous intestinal resection, clinical and biological disease activity, exposure to immunosuppressants, and exposure to anti-TNF (P < 0.005). Among patients exposed to anti-TNF, the Lémann Index was lower in those who were exposed in the first 2 years of their disease (P = 0.015). The mean IBD Disability Index was 28.8 ± 6.3 and ranged from 0 to 71 points. The factors associated with high disability score were: female gender, anal location, extra digestive manifestations, clinical and biological disease activity and exposure to anti-TNF (P < 0.005). No correlation was observed between the Lémann Index and IBD Disability Index (P = 0.15).
Conclusions: This is the first study to prospectively evaluate the Lémann Index and the IBD Disability Index in a large cohort of CD patients in a tertiary centre. Early introduction of anti-TNF treatment was associated with lower bowel damage scores, and no correlation was observed between the Lémann Index and the IBD Disability Index. Further dedicated prospective studies are necessary to confirm these results.
(© 2020 John Wiley & Sons Ltd.)

Comment in: Aliment Pharmacol Ther. 2020 Jun;51(11):1203-1204. (PMID: 32424924)
Comment in: Aliment Pharmacol Ther. 2020 Jun;51(11):1202-1203. (PMID: 32424926)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja